Mark Malek, MD
Public Health & General Preventive Medicine · Long Beach, CANPI 1962841346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $538 and has fallen 96.1% since, to $21 in 2025.
Across 85 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$300
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- AbbVie$165
- GSK$157
- Abbott$121
- Lilly USA, LLC$103
- plus $483 from 11 others
What the payments were for
- Food & beverage$1,512100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $300 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $183 |
| AbbVie(2 entities) | 4 | $165 |
| GSK | 9 | $157 |
| Abbott | 6 | $121 |
| Lilly USA, LLC | 6 | $103 |
| Pfizer | 5 | $90 |
| AstraZeneca | 4 | $69 |
| Galderma Laboratories, L.p. | 4 | $55 |
| Amarin Pharma, Inc. | 3 | $54 |
| Amgen | 2 | $51 |
| Astellas Pharma US Inc | 2 | $47 |
| Boehringer Ingelheim | 2 | $34 |
| Dexcom, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Smith+Nephew | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE$107
How this compares
$1,512 in reported general payments places this provider in the 85th percentile of 109 public health & general preventive medicine providers in California.
See all public health & general preventive medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 21 | $25,473 |
| Valsartan | 32 | $1,412 |
| Alcohol Prep PadsAlcohol Antiseptic Pads | 14 | $1,411 |
| Rosuvastatin Calcium | 36 | $1,171 |
| Comfort Ez Pen NeedlePen Needle, Diabetic | 12 | $1,111 |
| Ezetimibe | 12 | $417 |
| Atorvastatin Calcium | 39 | $417 |
| Azelastine Hcl | 12 | $381 |
| Amlodipine Besylate | 32 | $244 |
| Levothyroxine Sodium | 17 | $240 |
| Tamsulosin Hcl | 14 | $195 |
| Metformin Hcl | 28 | $188 |
| Losartan Potassium | 12 | $187 |
| Carvedilol | 22 | $152 |
| Escitalopram Oxalate | 13 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $300 | $25,47321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 109 public health & general preventive medicine providers in California.
Other public health & general preventive medicine in Long Beach
- Kathy leLong Beach$233
- Steven GalsonThousand Oaks$594K
- Ryan ZaneSan Bernardino$97K
- Ross MillerBeverly Hills$65K
- Daniel CosgroveIndian Wells$61K
- Philp DarneySan Francisco$13K
- Karen StuderLoma Linda$9K
- George RutherfordSan Francisco$9K
- Kate HaggertySan Marcos$8K
- Serena TonstadLoma Linda$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.